Molecular Partners AG (MOLN) stock
MOLNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 12, 2026Score 1/30
$2.86+0.16 (+5.98%)
Close on Nov 17, 2026Market cap $115.47MP/E –Yield –
Molecular Partners r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was CHF 40.19M, down 17.3% from the year before. The highest annual figure on record is CHF 56.08M in fiscal 2020.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | CHF 40.19M | -17.3% |
| FY2024 | Dec 31, 2024 | CHF 48.60M | -0.4% |
| FY2023 | Dec 31, 2023 | CHF 48.78M | -3.9% |
| FY2022 | Dec 31, 2022 | CHF 50.75M | -8.9% |
| FY2021 | Dec 31, 2021 | CHF 55.72M | -0.6% |
| FY2020 | Dec 31, 2020 | CHF 56.08M | +28.9% |
| FY2019 | Dec 31, 2019 | CHF 43.50M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | CHF 9.61M | -23.6% |
| Q2 FY2025 | Jun 30, 2025 | CHF 10.71M | – |
| Q2 FY2024 | Jun 30, 2024 | CHF 13.09M | – |
| Q2 FY2023 | Jun 30, 2023 | CHF 11.63M | – |
| Q2 FY2022 | Jun 30, 2022 | CHF 12.57M | – |
See a number that looks wrong?